Britannia Life Sciences Inc.
BLSIF
$0.0666
-$0.0114-14.62%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -473.86% | -278.88% | -219.76% | -223.11% | -66.48% |
| Total Depreciation and Amortization | -21.13% | -41.29% | -41.02% | -30.37% | -9.19% |
| Total Amortization of Deferred Charges | -- | -- | 15.08% | -49.62% | -- |
| Total Other Non-Cash Items | 206.71% | 239.28% | 274.35% | -52.59% | -271.35% |
| Change in Net Operating Assets | -84.43% | -27.66% | -1.30% | 1,122.17% | 829.69% |
| Cash from Operations | -124.53% | -63.25% | -50.99% | -56.97% | -43.56% |
| Capital Expenditure | -113.63% | 88.17% | 89.63% | 93.93% | 137.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -446.97% | -446.97% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -247.27% | -623.05% | -138.36% | -9.76% | 58.34% |
| Cash from Investing | 60.99% | 80.68% | 66.31% | -167.33% | -49.36% |
| Total Debt Issued | -- | -- | 3,197.01% | 3,197.01% | -- |
| Total Debt Repaid | -21.33% | 16.80% | -31.22% | -64.64% | -90.20% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 37.00% | 37.00% | 37.00% |
| Cash from Financing | 80.67% | 55.64% | 13.58% | 4.66% | -56.90% |
| Foreign Exchange rate Adjustments | 183.28% | 195.04% | -22.68% | -27.34% | -120.62% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.04% | 74.24% | -0.43% | -380.45% | -305.12% |